Kornimate/medical-research-clean huggingface dataset:
comparing hypofractionated radiotherapy boost to conventionally fractionated

Conditions: Prostate Cancer

Summary: the main purpose of study is to compare the effectiveness of hypofractionated imrt boost radiotherapy to conventional imrt boost radiotherapy for high-risk prostate cancer patients combined with androgen deprivation therapy.

additional objectives of the study for high-risk (non-metastatic) prostate cancer patients are as follows: 1. analysis of number of circulating tumor cells in peripheral blood as a prognostic/predictive factors for survival. 2. analysis of mirna expression levels (100, 141 and 143) in peripheral blood as a prognostic and predictive factors. 3. evaluation of the usefulness expression of selected proteins (pten, smad4, cyclin d1, spp1) as prognostic and predictive factors. 4. evaluation of the usefulness of the expression level of antigen-specific t cells, b-and nk cells as a prognostic factors. 5. evaluation of usefulness of the fiducial markers for localizing the prostate gland position during irradiation for the selected control imaging methods (2dkv, cbct, mvct).

Eligibility criteria:
inclusion criteria: * men from 40 to 75 years old with confirmed prostate adenocarcinoma, prostate biopsy will be performed \<180 days before the date of randomization, * completed assessment of tumor differentiation according to gleason grading allows to perform stratification; gleason score ≤ 7 versus gleason score\> 8, * general condition according to the classification of the eastern cooperative oncology group (ecog) 0 - 1), (appendix 1), * androgen deprivation therapy: prior radiotherapy (rt) (minimum 3 months before the start of rt), concurrently with rt and after rt during follow-up (24 months) , * high risk of prostate cancer progression defined as presence of at least one of the following factors: ct3, gleason\> 7, psa\> 20 ng / ml or presence of at least two of ct2c, gleason 7, psa in the range of 10.1 ng / ml to 19.9 ng / ml, ct defined by ajcc staging 7 edition, (appendix 2), * psa identified at least 10 days after the biopsy or before, and patients receiving fiansteryd 30 days after the cessation of therapy, * no regional and distant metastases confirmed by bone scintigraphy, chest radiograph, computed tomography/magnetic resonance imaging of the pelvis, * signing an informed consent to participate in a medical experiment (radiotherapy + biological material samples) (annex 3), * morphological and biochemical parameters within normal limits. exclusion criteria: * the presence of active cancer except skin cancer preceding period of 5 years prior to randomization, * early surgery (radical prostatectomy) or pelvic rt, * earlier hormonal therapy than is advocated in this study, * co-morbidities that may significantly affect the expectancy life of the patients * do not meet the criteria for inclusion.

Keywords: high risk prostate cancer radiotherapy hypofractionation
adherence to hydroxyurea in children with sickle cell anemia

Conditions: Sickle Cell Anemia

Summary: medication non-adherence is a true public health problem. despite advancements in the molecular understanding of disease and improvements in therapy, patient health outcomes will not improve unless patients take prescribed medications regularly. decreasing the gap between efficacious and effective therapy for patients with scd is an essential research agenda. hydroxyurea has been shown to be safe and efficacious in children and infants. however, the effectiveness of the prophylaxis depends on adherence to the recommended regimen. medication adherence in scd has previously been found to be sub-optimal in patients taking penicillin, desferoxamine, and pain medication. adherence to hu has been studied to some extent in children with scd. based on estimates of adherence in other chronic illness we expect approximately 50% of patients to be \>80% adherent with their hu administration. there is no gold standard for improving adherence to treatment. there have been a few attempts in the scd population to improve adherence. these include a day camp to promote education about desferoxamine and peer support, a combination of a slide-show about scd and it complications, weekly phone calls by the clinic social worker and a calendar, and a seven-phase educational program. given the striking improvements in the peripheral blood smear findings of patients with scd on hu therapy, with reduction in the numbers of sickled cells, we hypothesize that viewing the peripheral blood smear of patients with poor adherence to hu compared to a blood smear of someone on hu can be used to improve adherence in non-adherent patients. we will conduct a randomized trial between the intervention of regularly showing children and their parents the peripheral blood smear and standard care, including reminders of the importance of compliance and review of complete blood count parameters, including wbc, mcv, and hgb concentration. the outcome measures will be increase in hemoglobin concentration and %hbf and increase in perceived qol. qol will be measured with age-appropriate and parent/proxy pedsql™. medication adherence will also be monitored throughout the study with pharmacy prescription refills, physician assessment, and self-report via a visual analogue scale. adherence estimates, hemoglobin concentration, %hbf and qol will be measured at baseline, 3 months and 6 months.


Eligibility criteria:
inclusion criteria: * sickle cell anemia * on hydroxyurea for at least six months * age 2-17.9 years exclusion criteria: * none

Keywords: sickle cell anemia children hydroxyurea treatment adherence
effects of limb remote ischemic preconditioning for prevention of delirium in elderly patients after non-cardiac surgery

Conditions: Elderly Patients; Non-cardiac Surgery

Summary: to investigate whether limb remote ischemic preconditioning (lrip) could safely decrease the incidence of delirium in elderly patients after non-cardiac surgery.

remote ischaemic preconditioning may confer the cytoprotection in critical organs. we hypothesized that limb remote ischemic preconditioning (ripc) would safely decrease the incidence of delirium in elderly patients after non-cardiac surgery.the primary outcomes included the incidence of delirium in the first 7 days after surgery using the confusion assessment method for the intensive care unit (cam-icu) scale.the quality of recovery over a 6-month period was evaluated as well.secondary endpoints included length of stay in the hospital after surgery (from day of surgery to hospital discharge), occurrence of non-delirium postoperative complications, and all-cause 6-month mortality.

Eligibility criteria:
inclusion criteria: * elderly patients received elective non-cardiac surgery with general anesthesia * anticipated surgery time \> 2 hours exclusion criteria: * age \< 65 years old * acute coronary syndrome or myocardial infraction within 3 months * chronic obstructive pulmonary emphysema * serious hepatic dysfunction (child-pugh class c) * serious renal dysfunction (undergoing dialysis before surgery) * ejection fraction less than 40% * poor pulmonary function (pao2 \<60mmhg) * preoperative history of schizophrenia, epilepsy, parkinsonism, or myasthenia gravis * inability to communicate in the preoperative period (coma, profound dementia, or language barrier) * brain injury or neurosurgery

Keywords: elderly patients non-cardiac surgery ischemic preconditioning delirium
effectiveness of squatting position on constipation severity and defecation problems

Conditions: Constipation; Postoperative Care; Nursing Care

Summary: one of the most common nursing care problems after surgery is defecation problems and the risk of constipation. the aim of the study was to determine the effectiveness of the squatting position with footstool on the constipation severity and defecation problems in the postoperative period in patients with hernia surgery.

in this study, after the surgical procedure, the patients were placed in a squatting position by placing a stool under their feet in the toilet.

Eligibility criteria:
inclusion criteria: * hernia surgery in the general surgery clinic * between 18 and 65 years of age * bmi between normal and overweight (18.50-24,99 kg/m2: normal,25-29,99 kg/m2: overweight) * being able to establish verbal communication * volunteering to participate in the study * absence of mental confusion * having full consciousness and orientation * having no communication difficulties * having a constipation risk between moderate to high * using a water closet type toilet at home exclusion criteria: * having a low risk of constipation * patient who declined to participate in the study

Keywords: squatting position constipation defecation problems clinical nursing research
galilei lens professional vs. predicate devices: a comparison study

Conditions: Cataract

Summary: study question: how does the new galilei lens professional compare to predicate devices? study hypothesis: the galilei lens professional achieves a better precision in the postoperative, calculated target refraction with cataract surgeries than predicate devices, and it is more versatile in the measurable parameters as well as more user-friendly.

background: an accessory to the commercially available galilei dual-scheimpflug corneal topographer/keratometer with the name "ebr accessory" was developed by the company ziemer ophthalmic systems ag for the measurement of intraocular distances. the combination is called "galilei lens professional". the measurement principle is based on on short coherence interferometry/-reflectometry, which has gained wide-spread application and has been applied clinically, including one of the members of this study group, for the precise measurement of axial, intraocular distances (12.1.). such ebr accessory measurements, in combination with measurements by the galilei, may be applied to given intra-ocular lens (iol) types and iol equations, an permit the calculation of suggested iols that are implanted during cataract surgery, in order to achieve the desired vision correction. to register this accessory for sale, the precision and agreement to existing devices with similar applications ("predicate devices") must be demonstrated. one complete measurement consists of a cornea-topography/keratometry scan, followed immediately by three consecutive, axial biometry scans of the anterior segment (cornea and crystalline lens) and - after a short re-alignment - three consecutive, axial biometry scans of the retina. the measurement process is continuous, but divided in two steps. blinking by the patient is possible in between the two steps, which increases patient comfort and, in certain cases, measurement success. precision is evaluated by three repeated, complete measurements with the galilei lens professional and each predicate device. two standard devices with comparable optical technology that are used in routine cataract surgery were declared as predicate devices. these two devise are typically used in combination with standard keratometers, as which the galilei lens professional may be employed as well. goal: the comparison of the galilei lens professional to predicate devices with respect to precision in measuring postoperative, calculated target refractions in cataract patients, and versatility of measurable quantities.

Eligibility criteria:
inclusion criteria: * spherical equivalent between -10 d and +10 d * best-corrected va of 20/100 or better. exclusion criteria: * strabism * blepharitis * nystagmus * amblyopia * anisometropia (spherical equivalent \> 1d) * angle closure glaucoma * seizure disorder * brain damages * down syndrome * trisomy 13 or 18 * cerebral palsy * other serious disorders of the eye or central nervous systems
spanish lung liquid vs. invasive biopsy program (sllip)

Conditions: Lung Cancer

Summary: tumor derived cell free dna (cfdna) is increasingly used in the clinic to obtain genotype information about lung cancer, but its concordance with concurrent tumor-derived sequenced data is not known. the primary objective of this study is to demonstrate the non-inferiority of cfdna-based versus tumor tissue-based genotyping.

primary objective: to demonstrate the non-inferiority of cfdna-based versus tumor tissue-based genotyping as it pertains to the detection of clinically-actionable biomarkers in first line, treatment naïve, metastatic non-squamous nsclc. the following secondary objectives will be studied: * turn around time (tat) of cfdna vs. tissue results. * time to treatment (ttt) initiation. * quantity not sufficient rate (qns) of tissue for clinically-actionable biomarker testing. * tumor not detected (tnd) rate of cfdna in blood. * rescue rate of qns samples using cfdna-derived genotyping. * rate response for patients that are actionable biomarker positive (either in cdna or tissue) treated with target-drugs according investigator criteria. up to three recist assessments per patient will be retrospectively done by external personnel (no investigational team). * rate of discovery of genomically mediated, acquired resistance to targeted therapies in the biomarker-positive subsets.

Eligibility criteria:
inclusion criteria: * patients biopsy-proven, metastatic, previously untreated, non-squamous non-small cell lung cancer (nsclc). patients may have received adjuvant cytotoxic chemotherapy, but not targeted neo-adjuvant or adjuvant therapy. * age ≥ 18 years * ability to understand a written informed consent document, and the willingness to sign it. * willingness to provide blood sample at the time points defined in table 1 \[pre-treatment, day 14 (+/- 7 days) and end of study\]. * patient has or will have standard-of-care tissue genotyping ordered. * stable eastern cooperative oncology group (ecog) performance status ≤ 2 exclusion criteria: * pregnancy, recorded from clinical records * any concurrent, non-cutaneous, malignancy (with the exception of early stage non-invasive cervical cancer). any prior cancer must have occurred more than 5 years prior with no evidence of currently active disease
patient priorities care (ppc)

Conditions: Multiple Chronic Conditions

Summary: patient priorities care aligns healthcare decision-making and care by all clinicians with patients' own health priorities. patient priorities care involves not only the health outcome goals that patients want to achieve, but also their preferences for healthcare. this approach is about aligning what outcomes patients want from their healthcare with what they are willing and able to do to achieve these outcomes. the approach begins with a member of the healthcare team helping patients identify their health outcome goals and their care preferences and preparing them to interact with their clinicians around these goals and preferences. the goals and preferences are transmitted to the patient's clinicians who use them in decision-making and communication with the patient and other clinicians.

many older adults with multiple chronic conditions receive conflicting recommendations and care that may be fragmented across clinicians. older adults vary in what's most important when faced with tradeoffs and vary in the health-related activities they are willing and able to complete to achieve their desired outcomes. a potential solution to these problems is to move from decision-making predicated solely on disease-guidelines to decision-making based on achieving each patient's own specific health outcome goals (e.g., relief of symptoms sufficient to allow specific functional activity) within the context of what they are willing and able to do (i.e. care preferences) to achieve these outcomes. the primary aims of the patient priorities care (ppc) pilot is to assess the feasibility of aligning primary and specialty care to focus on the health priorities (i.e. specific and actionable outcome goals and care preferences) of older adults with multiple chronic conditions (mcc)

Eligibility criteria:
inclusion criteria: * age \>65 years * member of pro-health practice for \>=3 years * determined to be an appropriate candidate evidenced by any of the following: * multiple chronic conditions (presence of \>3 active health problems) * \>10 medications * ≥ 1 hospitalization over the past year * ≥ 2 emergency department visits over the past year * seen by \>2 specialists (excluding gyn and eye) over the past year exclusion criteria: * end stage renal disease * unable to consent (e.g. dementia) * in hospice or meeting hospice criteria * nursing home resident * not english speaking

Keywords: patient health priorities health outcome goals healthcare preferences
autistic features in relation to motor function and quality of life in children with an autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: although motor limitations are not currently considered a as clinical manifestation of autism spectrum disorder, should not be ignored due to their high incidence and considerable influence on life quality functional activity


Eligibility criteria:
inclusion criteria: * both sex, * age ranges from 3 to 5 years, * mild to moderate autistic features according to childhood autism rating scale , * were able to sit alone independently exclusion criteria: * significant visual or auditory defects, * history of cerebral palsy or psychiatric disorder (e.g attention deficit hyperactivity disorder)

Keywords: autism motor function quality of life autistic features
comparison of dry needling and dry cupping in positional fault of pelvis

Conditions: Myofascial Trigger Point Pain; Quadratus Lumborum Syndrome; Positional Fault of Pelvis; Myofascial Trigger Point in Quadratus Lumborum

Summary: this project was a randomized clinical trial conducted to compare the effects of dry needling and dry cupping in positional fault of pelvis due to myofascial trigger points in quadratus lumborum so that we can have best treatment option for patients with myofascial trigger points.

non probability convenient sampling was done. patients following eligibility criteria from physiotherapy department of islam central hospital, sialkot were considered. sample size was calculated with epitool calculator. 26 participants were randomly allocated in two groups equally via convenient sampling method. baseline assessment was done initially. group a was given dry needling technique and group b was given dry cupping along with conventional physiotherapy treatment (hot pack and stretching). duration of research was almost 6 months. participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. pre and post treatment readings were taken in 1st and 6th session over a 3 week period respectively. a follow up reading was also taken after 1 month for checking prolonged post treatment effects. assessment was done via pressure pain threshold scale, pelvic goniometer and measuring tape for assessing functional positional fault of pelvis and muscle length of quadratus lumborum. all participants were provided written informed consent prior to commencement of the procedures. they were free to quit the treatment at any stage of research. data was analyzed by using spss version 23.

Eligibility criteria:
inclusion criteria: * on palpation the presence of at least 1 active trigger point in quadratus lumborum. so the patient presents with low back pain. * patients presents with positional fault of pelvis (lateral tilt)(4). * patients having chronic low back pain for at least more than 6 months(3). * patients agree to get treatment sessions for the research work. exclusion criteria: * participants should not have taken any medications like analgesics, anti-coagulants, non-steroidal anti-inflammatory drugs or muscle relaxants during this study or even 3 days before this study. * participants should not have received any other treatment for the pain management, because it will affect the results of the study. * patients with bleeding disorders, local or systemic infection, acute muscle trauma. * patients with comorbid conditions. * patients with severe physical disability and true leg length discrepancy(1). * pregnant females

Keywords: dry needling dry cupping quadratus lumborum
db-1311 in combination with bnt327 or db-1305 in advanced/metastatic solid tumors

Conditions: Solid Tumors

Summary: a phase ii, multicenter, open-label trial of db-1311 in combination with bnt327 or db-1305 in participants with advanced/metastatic solid tumors

this is a phase ii, multicenter, open-label, two-part trial designed to evaluate the safety and preliminary efficacy of db-1311 in combination with bnt327 or db-1311 in combination with db-1305 in targeted participants. participants with recurrent, progressive as well as advanced, metastatic hepatocellular carcinoma (hcc), cervical cancer (cc), melanoma, head and neck squamous cell carcinoma (hnscc) or non-small cell lung cancer (nsclc) are eligible to participate in the trial.

Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 years or acceptable age according to local regulations at the time of voluntarily signing informed consent. * at least one measurable lesion as assessed by the investigator according to recist v1.1 criteria. * has a life expectancy of ≥ 3 months. * has an eastern cooperative oncology group (ecog) performance status (ps) of 0-1 * has adequate organ function within 7 days prior to enrollment/randomization, * has adequate treatment washout period prior to the first dose of trial treatment. exclusion criteria: * prior treatment with b7h3 targeted therapy. * prior treatment with antibody-drug conjugate with topoisomerase inhibitor. * is a candidate to locoregional treatment with potential to induce complete or near complete response and prolonged tumor control, per investigator's assessment. * has an uncontrolled concomitant or intercurrent illness, that in the opinion of the investigator, contra-indicates trial participation, limits compliance with trial procedures or substantially increases the risk of incurring aes. exclusion criteria: * 1. prior treatment with b7h3 targeted therapy. * prior treatment with antibody-drug conjugate with topoisomerase inhibitor. * is a candidate to locoregional treatment with potential to induce complete or near complete response and prolonged tumor control, per investigator's assessment. * has an uncontrolled concomitant or intercurrent illness, that in the opinion of the investigator, contra-indicates trial participation, limits compliance with trial procedures or substantially increases the risk of incurring aes. * has uncontrolled or significant cardiovascular disease.

Keywords: b7-h3 pd-l1/vegf-a trop2 adc hnscc hcc cc melanoma nsclc